A medication first known for glucose control and weight loss is now changing the conversation about a serious sleep disorder.
On December 20, 2024, the U.S. Food and Drug Administration approved Zepbound, a tirzepatide medicine from Eli Lilly, for adults with obesity and moderate to severe obstructive sleep apnea, alongside a reduced-calorie diet and more physical activity.
The decision matters because obstructive sleep apnea is not just loud snoring or a bad night. In a clinical program lasting 52 weeks, the drug cut breathing interruptions and also improved weight, low oxygen during sleep, inflammation, and blood pressure.
What sleep apnea does
Obstructive sleep apnea happens when the muscles and soft tissues in the throat relax too much during sleep. The airway narrows or closes, breathing stops or becomes shallow, oxygen can drop, and the brain briefly wakes the person up to reopen the airway.
This can repeat many times a night, often without the sleeper remembering it. The result may be morning headaches, poor focus, and that heavy daytime drowsiness that turns driving into a real risk.
Why weight is central
Excess weight is not the only cause of sleep apnea, but it is one of the biggest risk factors. Extra tissue in and around the throat can make the airway smaller and easier to block, especially when the muscles relax at night.
That is why weight loss and continuous positive airway pressure (CPAP) often sit side by side in sleep apnea care. CPAP pushes air through a mask to keep the airway open, but it does not directly treat obesity.
How tirzepatide works
Tirzepatide acts on two gut-hormone pathways that help regulate appetite, food intake, insulin release, and blood sugar. In practical terms, it can make people feel less hungry, slow the emptying of the stomach, and help the body respond to high glucose.
The medicine is injected under the skin once a week. It has been used to control blood sugar in certain people with type 2 diabetes, assist weight loss in some patients, and now treat obstructive sleep apnea in adults with obesity.
What the trial found
The SURMOUNT-OSA program included 469 adults with obesity and moderate to severe obstructive sleep apnea. One study enrolled people who could not or would not use positive airway pressure therapy, and the other included people already using that treatment.
Participants received either tirzepatide or placebo for 52 weeks. Researchers tracked the apnea-hypopnea index, which is simply the number of times per hour that breathing stops or becomes too shallow during sleep.
By the end, tirzepatide users had significantly fewer breathing events than the placebo groups. The American Diabetes Association reported weight reductions of 18% in one study and 20% in the other, along with better systolic blood pressure.
A drug, not a shortcut
Sally Seymour, who leads the agency division that reviewed the drug, called the approval “a major step forward for patients with obstructive sleep apnea.” Still, the wording is careful. This treatment is for certain adults with obesity, not everyone with sleep apnea.
Dr. Facundo Nogueira, head of the Sleep Laboratory at Hospital de ClĂnicas, told Infobae that the drug has, in general, a very good safety profile, with few serious adverse effects reported.
He also said the improvement appears tied to weight loss, so patients without obesity would not be expected to benefit in the same way.
That distinction matters. Some people have sleep apnea because of jaw shape, enlarged tonsils, nasal blockage, alcohol use, sedating medicines, or the way their airway collapses during sleep. For them, a weight-loss medicine may not solve the main problem.
CPAP may still matter
The most interesting part is not that tirzepatide replaces every existing treatment. It may work best, at least for many patients, as part of a broader plan that includes CPAP, movement, nutrition, and medical follow-up.
Nogueira noted that patients using CPAP who also lost weight with tirzepatide had stronger improvements in oxygenation than patients treated only with CPAP who did not lose weight. He also pointed to better blood pressure control and inflammation markers, two concerns that often travel with sleep apnea.
The safety question
Like other powerful medicines, tirzepatide comes with trade-offs. MedlinePlus lists nausea, vomiting, diarrhea, decreased appetite, constipation, and upset stomach among possible side effects, along with more serious symptoms that require urgent medical attention.
Nogueira also told Infobae that most reported symptoms are digestive, self-limited, and manageable, while pancreatitis cases are very isolated. But there is another practical barrier that patients know well before they reach the pharmacy counter: cost.
What comes next
Atul Malhotra, professor of medicine at the University of California San Diego School of Medicine and principal investigator of the study, said tirzepatide could be used with or without CPAP in some cases, a possibility that may reshape care for people with obesity-related sleep apnea.
The larger message is not that a weekly shot fixes sleep. It is that sleep apnea, obesity, blood pressure, and glucose control are deeply connected, and doctors now have one more tool to treat that cluster rather than chasing each problem separately.
The main study has been published in The New England Journal of Medicine.
